COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #216 of 237
12/18 Late treatment study
Matangila et al., PLOS ONE, doi:10.1371/journal.pone.0244272 (Peer Reviewed)
Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study
Source   PDF   Share   Tweet
55% lower death with HCQ+AZ. Retrospective 160 hospitalized patients in the Democratic Republic of Congo, 92% receiving HCQ+AZ, showing adjusted OR 0.24 [0.03-2.2].

Matangila et al., 12/18/2020, retrospective, DR Congo, Africa, peer-reviewed, median age 54.0, 12 authors.
risk of death, 54.9% lower, RR 0.45, p = 0.21, treatment 25 of 147 (17.0%), control 8 of 13 (61.5%), adjusted per study, odds ratio converted to relative risk.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.